Cognitive effects of dopamine depletion in the context of diminished acetylcholine signaling capacity in mice
Open Access
- 1 January 2012
- journal article
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 6 (1) , 171-183
Abstract
SUMMARY A subset of patients with Parkinson’s disease acquires a debilitating dementia characterized by severe cognitive impairments (i.e. Parkinson’s disease dementia; PDD). Brains from PDD patients show extensive cholinergic loss as well as dopamine (DA) depletion. We used a mutant mouse model to directly test whether combined cholinergic and DA depletion leads to a cognitive profile resembling PDD. Mice carrying heterozygous deletion of the high-affinity, hemicholinium-3-sensitive choline transporter (CHTHET) show reduced levels of acetylcholine throughout the brain. We achieved bilateral DA depletion in CHTHET and wild-type (WT) littermates via intra-striatal infusion of 6-hydroxydopamine (6-OHDA), or used vehicle as control. Executive function and memory were evaluated using rodent versions of cognitive tasks commonly used with human subjects: the set-shifting task and spatial and novel-object recognition paradigms. Our studies revealed impaired acquisition of attentional set in the set-shifting paradigm in WT-6OHDA and CHTHET-vehicle mice that was exacerbated in the CHTHET-6OHDA mice. The object recognition test following a 24-hour delay was also impaired in CHTHET-6OHDA mice compared with all other groups. Treatment with acetylcholinesterase (AChE) inhibitors physostigmine (0.05 or 0.1 mg/kg) and donepezil (0.1 and 0.3 mg/kg) reversed the impaired object recognition of the CHTHET-6OHDA mice. Our data demonstrate an exacerbated cognitive phenotype with dual ACh and DA depletion as compared with either insult alone, with traits analogous to those observed in PDD patients. The results suggest that combined loss of DA and ACh could be sufficient for pathogenesis of specific cognitive deficits in PDD.Keywords
This publication has 97 references indexed in Scilit:
- Longitudinal Changes in Cognition in Parkinson’s Disease with and without DementiaDementia and Geriatric Cognitive Disorders, 2011
- Modes and Models of Forebrain Cholinergic Neuromodulation of CognitionNeuropsychopharmacology, 2010
- Lentiviral Overexpression of GRK6 Alleviates l -Dopa–Induced Dyskinesia in Experimental Parkinson’s DiseaseScience Translational Medicine, 2010
- The cognitive impact of anticholinergics: A clinical reviewClinical Interventions in Aging, 2009
- Double Dissociation of the Effects of Medial and Orbital Prefrontal Cortical Lesions on Attentional and Affective Shifts in MiceThe Journal of Neuroscience, 2008
- Impaired learning and memory in Pitx3 deficient aphakia mice: A genetic model for striatum-dependent cognitive symptoms in Parkinson's diseaseNeurobiology of Disease, 2008
- Noradrenergic, but not cholinergic, deafferentation of prefrontal cortex impairs attentional set-shiftingNeuroscience, 2008
- Arrestins and two receptor kinases are upregulated in Parkinson's disease with dementiaNeurobiology of Aging, 2008
- Altered expression and subcellular distribution of GRK subtypes in the dopamine‐depleted rat basal ganglia is not normalized byl‐DOPA treatmentJournal of Neurochemistry, 2007
- Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's diseaseInternational Journal of Geriatric Psychiatry, 2004